Disclosures DePuy Consultant Medtronic Consultant Stryker - - PDF document

disclosures
SMART_READER_LITE
LIVE PREVIEW

Disclosures DePuy Consultant Medtronic Consultant Stryker - - PDF document

Primary Bone Tumors: Spine Surgery Live -Video Techniques Mobile Spine Christopher Ames MD Professor of Neurosurgery and Orthopedic Surgery Director of Spine Tumor And Deformity Surgery UCSF Department of Neurosurgery Disclosures DePuy


slide-1
SLIDE 1

1

Primary Bone Tumors: Spine Surgery Live -Video Techniques Mobile Spine

Christopher Ames MD Professor of Neurosurgery and Orthopedic Surgery Director of Spine Tumor And Deformity Surgery UCSF Department of Neurosurgery

Disclosures

DePuy Medtronic Stryker Docters Research Group Fish & Richardson StrykerBiomet Spine Consultant Consultant Consultant Stock Shareholder (excluding mutual funds) P.C. Consultant

slide-2
SLIDE 2

2

Outline

 Background of Grading and Staging  Examples with Treatment Implications (Mobile Spine)

Modern Spine Tumor Surgery

Metastatic Spine Tumors Primary Spine Tumors

slide-3
SLIDE 3

3

 Primary tumors rely more on

surgical treatment at initial surgery

 Diagnosis  Histology  Staging System  Oncological  Location  Surgical  Treatment Planning  Adjuvant yes/no/pre/post  Surgery

wide/marginal/intralesional (part/whole)

 Surgical Technique

Primary Tumors

Histology

  • Chondrogenic
  • Osteogenic
  • Fibrogenic
  • Fibrohistiocytic
  • Osteoclastic GC-rich
  • Vascular
  • Neuro/Ectodermal
  • Notochordal
  • Undefined/Pseudotumoral
slide-4
SLIDE 4

4

Surgical staging system

Stage Definition 1 G0 T0 M0 Benign latent 2 G0 T0 M0 Benign active 3 G0-1 T0-1 M0 Benign aggressive I A G1 T1 M0 Malignant, low grade, intracompartmental I B G1 T2 M0 Malignant, low grade, extracompartmental II A G2 T1 M0 Malignant, high grade, intracompartmental II B G2 T2 M0 Malignant, high grade, extracompartmental III G any T any M1 Malignant, any grade, any extent, distant metastasis

Enneking et al,1983

1 G0 T0 M0 Latent 2 G0 T0 M0 Active 3 G0 T1/2 M0/1 Aggressive

1.Capsule, 2.Pseudocapsule

C B A D E

Benign Tumor

slide-5
SLIDE 5

5

Grade 1

Hemangioma

Grade 2 Grade 3

slide-6
SLIDE 6

6

Osteochondroma

 Low grade  Benign  Symptomatic  Marginal

Excision

20 yo f

slide-7
SLIDE 7

7

Benign Tumor-Osteoid Osteoma Treatment

 NSAIDS  RFA  Intralesional

curettage

 Associated

scoliosis 13 yo female

ABC

Modern Tx

 Serial Embolization  Intralesional embolization  Intralesional resection

 Not able to embolize  Mechanical Instabiliy

 Denosumab?

slide-8
SLIDE 8

8

Posterior resection and reconstruction of C1 lateral mass for ABC

slide-9
SLIDE 9

9

ABC vs GCT vs Telangiectatic OS

 Bx - GCT vs ABC  Rebx- GCT vs OS  3 months denosumab

30 yo male back pain

Indications for En Bloc Resection

Curr Opinion Orthopedics 1999

slide-10
SLIDE 10

10

GCT Chordoma

Semin Spine Surg 21:76-85

Terminology

En bloc resections without tumor-free margins

Intralesional: The tumor periphery is violated and the tumor is not covered by healthy tissue. Marginal: The pathologist describes histologically a thin layer of healthy muscle, bone, or an endothelial membrane continuously covering the tumor mass Wide: A fascial barrier represents a wide margin… 1 cm of muscle or cancellous bone sometimes is not enough and a 2 cm barrier may be required to consider the margin wide.

Boriani Seminars in Oncology

slide-11
SLIDE 11

11

WBB Staging Osteoblastoma

Benign

 Type 3  20% recurrence

intralesional

 En Bloc Excision  Associated ABC

slide-12
SLIDE 12

12

Operative Plan

slide-13
SLIDE 13

13

slide-14
SLIDE 14

14

slide-15
SLIDE 15

15

Giant cell tumor

  • Chondrogenic
  • Osteogenic
  • Fibrogenic
  • Fibrohistiocytic
  • Osteoclastic GC-rich
  • Vascular
  • Neuro/Ectodermal
  • Notochordal
  • Undefined/Pseudotumoral
slide-16
SLIDE 16

16

Recurrent GCT L1-2

Options?

slide-17
SLIDE 17

17

slide-18
SLIDE 18

18

Giant cell Tumor (location)

 Denosumab

  • The efficacy assessment included 49

patients who had the opportunity to be

  • n denosumab treatment for at least 6

months.

  • After 6 months, 47 patients (96%) were

free of disease progression based on subjective assessment of disease status

20 40 60 80 100 No Disease Progression Disease Progression Proportion of Patients (%)

slide-19
SLIDE 19

19

IA Intra-comp; thin capsule, tumor in pseudocapsule IB Extra-comp (Zone A,D,E) chordoma, chondrosarcoma IIA Intra-comp; tumor in PC, Osteosarcoma, ES IIB Extra-comp (Zone A,D,E)

1.Capsule, 2.Pseudocapsule, 3.Tumor invation to pseudocapsule, 4.Skip metastases

C B A D E

High grade Low grade

Malignant Tumor

slide-20
SLIDE 20

20

 How to access contralateral

nerve root ?

 Lateral retraction of specimen

slide-21
SLIDE 21

21

slide-22
SLIDE 22

22

slide-23
SLIDE 23

23

Chordoma

  • Chondrogenic
  • Osteogenic
  • Fibrogenic
  • Fibrohistiocytic
  • Osteoclastic GC-rich
  • Vascular
  • Neuro/Ectodermal
  • Notochordal
  • Undefined/Pseudotumoral

En Bloc Resection Technique Technique

 1. Single stage, posterior

High to mid thoracic, sacrectomy  2. 2 stage, posterior/anterior Cervical, Lower thoracic, lumbar, ? Vessel or

large extracompartmental disease

slide-24
SLIDE 24

24

Tomita Threadwire Saw System Tomita Threadwire Saw System

slide-25
SLIDE 25

25

First Step-pass wire saw

slide-26
SLIDE 26

26

Anterior Finger Dissection

slide-27
SLIDE 27

27

Single stage, posterior High to mid thoracic

slide-28
SLIDE 28

28

slide-29
SLIDE 29

29

slide-30
SLIDE 30

30

Standard 2 stage P/A Chordoma

slide-31
SLIDE 31

31

slide-32
SLIDE 32

32

slide-33
SLIDE 33

33

slide-34
SLIDE 34

34

Chordoma 5 level

slide-35
SLIDE 35

35

Spinal Cord Perfusion after Segmental Ligation

NEW for Chordoma—Combined Hybrid Surgery

Preop SRS 2500cGy/5, max tumor 3450cGy

slide-36
SLIDE 36

36

3 Stage P/L/R

 IVC Filter  PSF/I T2-T11, posterior osteotomy and nerve

sacrifice

 Left Thoracotomy, aortic dissection, 3.25 level  Right Thoracotomy, esophageal dissection,

delivery

slide-37
SLIDE 37

37

slide-38
SLIDE 38

38

Chordoma (Location)

slide-39
SLIDE 39

39

Case 4 Spondylectomy Technique En Bloc marginal -contaminated at vertebral a.

SAC Preserve

Bilateral Transverse Cervical Exposure

slide-40
SLIDE 40

40

4 rod reconstruction

slide-41
SLIDE 41

41

3 4 5

6

slide-42
SLIDE 42

42

Chondrosarcoma

  • Chondrogenic
  • Osteogenic
  • Fibrogenic
  • Fibrohistiocytic
  • Osteoclastic GC-rich
  • Vascular
  • Neuro/Ectodermal
  • Notochordal
  • Undefined/Pseudotumoral
slide-43
SLIDE 43

43

2 Stage A/P Thoracic 270 SpondylectomyChondrosarcoma 2 Stage Thoracic Spondylectomy Chondrosarcoma

slide-44
SLIDE 44

44

270 degree resection L2-3 chondrosarcoma A/P

 32 yo male  Needle biospy with chondrosarcoma

slide-45
SLIDE 45

45

slide-46
SLIDE 46

46

Osteosarcoma

 Preoperative adjuvant

therapy

 Response to therapy

predictive of outcome

 Refinement of surgical

margins

  • Chondrogenic
  • Osteogenic
  • Fibrogenic
  • Fibrohistiocytic
  • Osteoclastic GC-rich
  • Vascular
  • Neuro/Ectodermal
  • Notochordal
  • Undefined/Pseudotumo

ral

Ewings Sarcoma

Preoperative Adjuvant Therapy

  • Chondrogenic
  • Osteogenic
  • Fibrogenic
  • Fibrohistiocytic
  • Osteoclastic GC-rich
  • Vascular
  • Neuro/Ectodermal
  • Notochordal
  • Undefined/Pseudotumoral
slide-47
SLIDE 47

47

P32 Brachytherapy

Ex: Leiomyosarcoma

 Adjuvant therapy  P32 to margin  Dural margin  Shape radiation targets

for SRS

slide-48
SLIDE 48

48

P32

 Beta emitting radioisotope

(1-2 Gy/minute)

 Embedded in thin plastic

polymer

 Half-life 14 days

  • Conforms to the dura
  • Handled without shielding
  • Custom fit at surgery to

the target

 FDA approved

slide-49
SLIDE 49

49

Soft Tissue Sarcoma Primary vs Metastatic Bone grafting demand

Recurrent CS 5 years later…

slide-50
SLIDE 50

50

Thanks to the Primary Tumor Team!

 Vedat Deviren Orthopedics  Igor Barani Rad Onc  Pierre Theodore Thoracic  Ivan El Sayed ENT  Mika Varma Colorectal  Bill Hoffman Plastics  Charles Eichler Vascular  Rebecca Mustille PT